Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$14.13 USD

14.13
1,850,840

-1.25 (-8.13%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $14.13 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Investors Should Buy Integra LifeSciences Now

by Zacks Equity Research

The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.

    Zacks Equity Research

    3 Plastic & Reconstructive Surgery Stocks Looking Good

    by Zacks Equity Research

    Consider these three stocks for raking in grand returns from the fast-growing plastic and reconstructive surgery market.

      Zacks Equity Research

      Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm

      by Zacks Equity Research

      Integra (IART) widens its tissue technology segment with the launch of Revize/Revize-X Collagen Matrix for plastic and reconstructive surgery.

        Zacks Equity Research

        Integra Rides High on Product Launches, Competition Rife

        by Zacks Equity Research

        Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.

          Zacks Equity Research

          Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line

          by Zacks Equity Research

          Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.

            Zacks Equity Research

            Integra Closes Codman Buyout, Strengthens Neurosurgery Arm

            by Zacks Equity Research

            With Codman's acquisition by Integra (IART), the neurosurgery business is likely to drive the company's 2018 adjusted earnings per share with a minimum yield of 22 cents.

              Zacks Equity Research

              Integra Divests Assets to Natus, Paves Way for Codman Buyout

              by Zacks Equity Research

              Integra LifeSciences' (IART) divestment of certain neurosurgery assets to Natus Medical is part of the company's agenda to meet closing conditions toward the Codman neurosurgery business buyout.

                Zacks Equity Research

                Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss

                by Zacks Equity Research

                Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.

                  Zacks Equity Research

                  Integra LifeSciences (IART) Up 8.5% Since Earnings Report: Can It Continue?

                  by Zacks Equity Research

                  Integra LifeSciences (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Zacks Equity Research

                    Integra LifeSciences to Offer aap's LOQTEQ System in the US

                    by Zacks Equity Research

                    Global medical technology major, Integra LifeSciences Holdings Corporation (IART) recently inked an agreement with aap Implantate AG, a Berlin-based trauma product maker.

                      Zacks Equity Research

                      Integra Lifesciences Hits 52-Week High on Product Launches

                      by Zacks Equity Research

                      Share price of Plainsboro NJ-based Integra Lifesciences Corporation (IART) reached a new 52-week high of $47.50 on May 19, finally closing a tad lower at $47.39.

                        Zacks Equity Research

                        Integra LifeSciences (IART) Misses Q1 Earnings, Retains View

                        by Zacks Equity Research

                        Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 39 cents in the first quarter of 2017, which marked a 2.6% increase from the year-ago number.

                          Zacks Equity Research

                          Integra LifeSciences (IART) Q1 Earnings: A Beat in Store?

                          by Zacks Equity Research

                          We expect Integra LifeSciences Holdings Corporation (IART) to beat expectations when it reports its first-quarter 2017 results, after market close on Apr 26.

                            Zacks Equity Research

                            Integra LifeSciences Expands Cadence System Commercially

                            by Zacks Equity Research

                            Integra LifeSciences Holdings Corporation (IART), a global medical technology company, recently announced full commercial expansion of its Cadence Total Ankle System.

                              Zacks Equity Research

                              Integra (IART) Titan Reverse Launch Expands Extremity Line

                              by Zacks Equity Research

                              Integra LifeSciences (IART) recently broadened its extremity product line with the launch of its Titan Press-Fit Reverse Shoulder for Fracture.

                                Zacks Equity Research

                                Integra (IART) Posts In-Line Q4 Earnings, Issues 2017 View

                                by Zacks Equity Research

                                Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 52 cents in the fourth quarter of 2016, up 18% from the year-ago adjusted number.

                                  Zacks Equity Research

                                  Integra LifeSciences at 52-Week High on Deals, View Update

                                  by Zacks Equity Research

                                  Shares of Integra LifeSciences Holdings Corporation (IART), a global leader in medical technology, scaled a new 52-week high of $45.50 on Jan 10, closing a tad lower at $44.90.

                                    Kevin Matras headshot

                                    Why the P/S Ratio is My Favorite Valuation Metric

                                    by Kevin Matras

                                    This week, Kevin Matras shows how to use the Price to Sales ratio. Highlighted stocks include BECN, CORE, HNI, IART and POST.